Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of transfer rna molecules and fragments thereof for preventing or treating heart disease

A heart disease, molecular technology applied to a combination of drugs for the prevention or treatment of heart disease. , in the field of drugs for the prevention or treatment of heart disease, which can solve problems such as toxic side effects and large amount of treatment

Active Publication Date: 2021-02-26
睿纳珠海横琴生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ginseng roots have been used as a traditional Chinese medicine for thousands of years to "invigorate qi and nourish blood". The main components of ginsenosides and polysaccharides have a significant protective effect on myocardial ischemia, but their therapeutic dosage is relatively large, which is easy to harm the human body. produce serious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of transfer rna molecules and fragments thereof for preventing or treating heart disease
  • Use of transfer rna molecules and fragments thereof for preventing or treating heart disease
  • Use of transfer rna molecules and fragments thereof for preventing or treating heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139] Example 1 Isolation of RNA molecules from plants of the genus Panax

[0140] The roots of ginseng (Panax ginseng C.A. Mey) were freshly collected and immediately stored in liquid nitrogen until use. By using the method of PARI (polysaccharase-aidedRNAisolation), from ginseng (Panax ginsengC.A.Mey) to extract RNA with a length of 200 nucleotides or less, that is, small RNA species, the method was developed by the inventor and his laboratory Personnel first described. Briefly, plant tissues were ground into a fine powder in liquid nitrogen and then homogenized in TRIzol reagent using a digital dispersion unit (IKA, Germany). After thorough lysis at room temperature for 10 min, an equal volume of chloroform was added, followed by centrifugation at 12,000 × g for 15 min at 4°C. Collect the supernatant and add 1 / 25 volume of sodium chloride and 1.25 times the volume of cold ethanol, and co-precipitate at -20°C for 30 minutes. The collected precipitate was hydrolyzed wit...

Embodiment 2

[0144] Synthesis of Example 2 RNA Molecules

[0145] The present inventors designed and synthesized RNA molecules with a length of about 19 to 22 bp based on the 58 isolated tRNA sequences in Example 1. In particular, a tRNA sequence is considered to have at least 3 parts, namely a 5'-terminal part (5'-t), a 3'-terminal part (3'-t), and an anticodon part. Each specially designed RNA molecule contains either part. For example, a designed RNA molecule containing the 5' terminal portion of the corresponding full-length tRNA sequence is called a 5'-t group RNA molecule; a designed RNA molecule containing the 3' terminal part of the corresponding full-length tRNA sequence is called a 3'-t group RNA molecule. Group RNA molecules; RNA molecules designed to contain the anticodon portion of the corresponding full-length tRNA sequence are called anticodon group RNA molecules. As shown in Table 2, the RNA molecule having the sense sequence selected from SEQ ID NO:1 to SEQ ID NO:232 a...

Embodiment 3

[0146] Example 3 The protective effect of RNA molecules on cardiomyocytes

[0147] Rat cardiac H9C2 cell line was cultured in DMEM medium containing 10% FBS and 1% penicillin / streptomycin, and in 5% CO 2 Cultured in a 37°C incubator with a humid atmosphere.

[0148] For cell viability assays, exponentially growing cells of cardiomyocytes H9C2 were seeded at a density of 5000 cells per well in 96-well microplates in 100 μL of medium and allowed to adhere for 24 hours before treatment. For the cardiomyocyte hypoxia model, the RNA molecules of continuous concentration obtained in Example 1 were added to H9C2 cells and placed in KRB buffer (sodium chloride 115mM, potassium chloride 4.7mM, calcium chloride 2.5mM, diphosphate Potassium hydrogen 1.2 mM, magnesium sulfate 1.2 mM, sodium bicarbonate 24 mM, HEPES buffer 10 mM, pH 7.4), and cultured at 37° C. for 3 hours in an anaerobic container (Stem Cell Technologies, USA). In the hypoxia-reoxygenation model of cardiomyocytes, H9C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Application of transfer RNA Molecules and their derived fragments for prevention or treatment of heart disease. The present invention provides a method of preventing or treating a subject suffering from heart diseases comprising administration of transfer RNA molecules and fragments derived from transfer RNA molecules or its functional variants or homologous to the subject, wherein the RNA molecules isolated from or derived from a plant of the genus Panax. The present invention also provides a pharmaceutical composition for the prevention or treatment of heart diseases comprising said effective amount of RNA molecule and a pharmaceutically tolerable vector, virus or excipient. The present invention provides a method for the prevention or treatment of a subject suffering from a heart disease. It is found that transfer RNA molecules from ginseng are particularly effective in the treatment of heart diseases, and also have a restorative effect on the myocardial cytoskeleton after ischemia-reperfusion injury.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the use of a transfer RNA molecule isolated or derived from plants of the genus Panax in the preparation of medicines for preventing or treating heart diseases. The invention also provides a drug combination for preventing or treating heart diseases. Background technique [0002] Coronary heart disease (CHD) has become the most common cause of death worldwide. Traditional Chinese medicine (TCM) has been widely used in the treatment and prevention of coronary heart disease, and a large number of research efforts have contributed to the study of the effectiveness of isolated small molecules such as saponins, terpenoids, flavonoids, etc. in the treatment of coronary heart disease. For example, some saponins such as ginsenosides have been found to have an anti-ischemic effect on the myocardium. However, most of them usually have relatively large side effects on the human body. Furthermore,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/713A61P9/10A61P9/00C12N15/63
CPCA61K31/713A61P9/00A61P9/10C12N15/63A61K31/7105A61K47/554C12N15/11A61K47/543
Inventor 姜志宏胡姱严通萌
Owner 睿纳珠海横琴生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com